You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 10,485,844

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,485,844
Title:Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
Abstract: The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.
Inventor(s): Radin; Allen (New York, NY), Graham; Neil (Croton-on-Hudson, NY), Akinlade; Bolanle (White Plains, NY), Pirozzi; Gianluca (Bridgewater, NJ), Sun; Xing (Bridgewater, NJ), Hultsch; Thomas (Bridgewater, NJ), Shumel; Brad S. (Chappaqua, NY), Bansal; Ashish (White Plains, NY)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) Sanofi Biotechnology (Paris, FR)
Application Number:15/711,815
Patent Claims:see list of patent claims

Details for Patent 10,485,844

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Jubilant Hollisterstier Llc POSITIVE SKIN TEST CONTROL - HISTAMINE histamine INJECTION 103891 1 1995-06-15   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) Sanofi Biotechnology (Paris, FR) 2037-08-18 search
Regeneron Pharmaceuticals DUPIXENT dupilumab INJECTABLE; INJECTION 761055 001 2017-03-28   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) Sanofi Biotechnology (Paris, FR) 2037-08-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.